Skip to main content
DCTH
NASDAQ Industrial Applications And Services

Delcath Systems Beats Q2 Estimates, Raises Full-Year Guidance on HEPZATO Momentum

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$14
Mkt Cap
$436.008M
52W Low
$8.12
52W High
$13.74
52W Position info
72% above low
Off High info
at 52W high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

DCTH sits 72% above its 52-week low of $8.12.

Summary

Delcath Systems reported Q2 revenue of $29.1M, beating estimates by 11%, and raised full-year 2026 guidance to $104M–$108M. Net income reached $2.7M, with cash and investments of $95.9M.


Key Events · Earnings and Guidance · DCTH

  • Q2 Revenue Beat

    Revenue of $29.1M exceeded the $26.3M consensus by 11%, driven by HEPZATO KIT sales of $27.2M.

  • Full-Year Guidance Raised

    Management lifted 2026 revenue guidance to $104M–$108M, up from prior expectations, reflecting strong demand and commercial execution.

  • Return to Profitability

    Net income was $2.7M for Q2, compared to $2.7M a year ago, as gross margin expanded to 89.8% on higher sales.

  • Strong Balance Sheet

    Cash, equivalents, and short-term investments totaled $95.9M at quarter-end, with no debt, providing ample runway for clinical trials and operations.


Analysis · DCTH · Industrial Applications And Services

A strong Q2 for Delcath Systems saw revenue of $29.1 million beat consensus by 11%, prompting management to raise full-year guidance to $104–$108 million. The company swung to a net profit of $2.7 million, supported by expanding HEPZATO adoption and a healthy cash position of $95.9 million. These results confirm commercial traction for its liver-directed cancer therapy and provide a clear growth trajectory, though operating expenses are rising as clinical trials expand.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DCTH was trading at $14.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $436M. The 52-week trading range was $8.12 to $13.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DCTH - Latest Insights

DCTH
Nov 09, 2026, 11:17 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $18.77
Real-time Price: $20.10 info
Change: +$1.33 (+7%) info
Market Cap: $702.023M info
DCTH
Nov 09, 2026, 9:01 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.00
Real-time Price: $20.10 info
Change: +$2.10 (+12%) info
Market Cap: $702.023M info
DCTH
Nov 09, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.68
Real-time Price: $20.10 info
Change: +$3.42 (+21%) info
Market Cap: $702.023M info
DCTH
Nov 09, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $14.94
Real-time Price: $20.10 info
Change: +$5.16 (+35%) info
Market Cap: $702.023M info
DCTH
Aug 06, 2026, 8:16 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $14.50
Real-time Price: $20.10 info
Change: +$5.60 (+39%) info
Market Cap: $702.023M info